New combo therapy for ulcerative colitis shows promise in Real-World study

This study looks at whether adding a second drug (vedolizumab) to the standard drug upadacitinib works better than upadacitinib alone for people with moderate-to-severe ulcerative colitis. Researchers will review medical records from 150 adults across six hospitals in China to see which treatment leads to more symptom relief and fewer side effects after 8 weeks. The goal is to provide real-world evidence to help doctors choose the best treatment plan.